Lung Cancer Early Screening: Low-Dose CT Is Not for Everyone, But These Groups Must Have It

Introduction

Lung cancer, often called the "silent killer," accounts for approximately 828,000 new cases and 657,000 deaths annually in China, ranking first among all malignant tumors. More alarmingly, about 75% of patients are diagnosed at advanced stages, with a five-year survival rate below 20%. However, if detected and surgically treated at an early stage (Stage I), the five-year survival rate can exceed 90%.

The key to early detection lies in the choice of screening tools. Many people undergo chest X-rays during health check-ups, believing that "a clear X-ray means safety," but in reality, chest X-rays have an extremely low detection rate for pulmonary nodules smaller than 1 cm, with a missed diagnosis rate as high as 60%-80%. The screening method that truly reduces lung cancer mortality is low-dose spiral computed tomography (LDCT).

However, LDCT is not "for everyone"; it has specific target populations and screening intervals. Blindly undergoing it may cause unnecessary radiation exposure and anxiety, while failing to undergo it when indicated may miss the optimal treatment window. This article will break down the correct approach to LDCT and provide practical recommendations for international patients.

What Exactly Makes Low-Dose CT "Low"?

Low-Dose Computed Tomography (LDCT) is a CT examination specifically designed for lung screening. Its radiation dose is only one-fifth to one-tenth that of a conventional chest CT, approximately 0.5-1.5 mSv, which is about half of the natural background radiation we receive annually (approximately 2.4 mSv), and even lower than a single mammogram.

The principle involves reducing the tube current and tube voltage, significantly decreasing radiation exposure while maintaining sufficient image quality for diagnosis. For high-contrast lesions such as pulmonary nodules, LDCT is fully adequate, and the higher dose of conventional CT is unnecessary in this context.

The evidence is robust: The National Lung Screening Trial (NLST) in the United States enrolled over 53,000 high-risk individuals and showed that annual LDCT screening, compared with chest X-ray, reduced lung cancer mortality by 20% and all-cause mortality by 6.7%. The European NELSON study also confirmed that LDCT screening reduced lung cancer mortality by 26% in men and up to 39% in women.

Therefore, LDCT is globally recognized as the "gold standard" for lung cancer screening, but its application has strict indications.

Who Should Be Screened? Three High-Risk Groups Must Undergo Regular Screening

According to the Chinese Guidelines for Lung Cancer Screening and Management (2024 edition) and the US NCCN guidelines, annual LDCT screening is recommended for the following high-risk groups:

Age ≥50 years with a smoking history of at least 20 pack-years (pack-years = packs smoked per day × years of smoking). For example, smoking 1 pack per day for 20 years, or 2 packs per day for 10 years, both reach 20 pack-years.

- Those who quit smoking less than 15 years ago still have elevated risk and should continue screening.

- If cessation exceeds 15 years, screening frequency may be reduced or discussed with a physician.

Age ≥50 years with long-term passive smoking exposure (secondhand smoke exposure ≥20 years) and long-term exposure to occupational or environmental carcinogens such as kitchen fumes, asbestos, radon, or coal smoke.

- The high incidence of lung cancer among Chinese women is closely related to kitchen fumes and secondhand smoke; this group should not be overlooked.

Family history of lung cancer (a first-degree relative such as a parent, child, or sibling with lung cancer) and age ≥40 years.

- Family history is an independent risk factor; even non-smokers have significantly elevated risk.

Additionally, individuals with chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, or a history of prior malignancy are also advised to undergo earlier screening.

Note: If you do not fall into any of the above categories and have no symptoms, routine LDCT is not recommended, as screening may lead to false positives, overdiagnosis, and anxiety, with harms outweighing benefits.

Pulmonary Nodules: If Found, Don't Panic, But Don't Ignore

Because LDCT has a high detection rate, the discovery rate of pulmonary nodules has also increased. In China, approximately 30%-40% of screened individuals are found to have pulmonary nodules, but over 90% of these are benign (e.g., inflammation, scars, lymph nodes).

The management of pulmonary nodules centers on "risk assessment plus dynamic follow-up." Based on nodule size, density (solid, ground-glass, or part-solid), morphology (margins, spiculation, calcification), and your personal risk factors, doctors provide stratified management recommendations.

Micro-nodules (<5 mm): For low-risk individuals, a repeat LDCT is typically performed after 12 months; if unchanged, annual follow-up is sufficient thereafter.

Small nodules (5-8 mm): A repeat scan is recommended after 6-12 months, with next steps determined by growth.

Medium nodules (8-15 mm): Contrast-enhanced CT, PET-CT, or short-term (3-month) follow-up may be considered; biopsy may be necessary.

Large nodules (>15 mm) or rapidly growing nodules: These have a high likelihood of malignancy and require prompt multidisciplinary consultation, with consideration of surgery or minimally invasive biopsy.

It is important to emphasize that ground-glass nodules (GGNs), despite sounding alarming, are often indolent and slow-growing; many only require regular follow-up rather than immediate surgery. However, mixed ground-glass nodules (part-solid) with increasing solid components warrant heightened vigilance.

Additionally, liquid biopsy (e.g., circulating tumor DNA testing) can serve as an adjunct for monitoring indeterminate nodules, but it is not yet standard and cannot replace imaging follow-up.

How International Patients Can Choose Screening and Follow-Up Plans

For patients coming to China from overseas, or foreigners living in China, lung cancer screening strategies should consider local medical resources and individual circumstances.

Advantages of screening in China: LDCT is low-cost (approximately 300-800 RMB), requires no appointment wait, and results are available the same day, offering excellent value. Additionally, Chinese thoracic specialists have extensive experience in managing pulmonary nodules, particularly in minimally invasive surgery (e.g., uniportal video-assisted thoracoscopic surgery), which results in less trauma and faster recovery.

Pre-screening preparation: If you have recently undergone CT abroad, be sure to bring the original imaging disc or electronic files for comparison. Chinese radiologists place great importance on comparing current and prior images, which significantly improves diagnostic accuracy.

Follow-up recommendations: If nodules are stable and low-risk, consider extending the follow-up interval to 12 months, and use the online consultation feature on the Meijiakang platform to upload imaging reports for interpretation by domestic experts, saving travel time.

Cost estimation: If you are concerned about costs, use our cost estimator tool, enter the examination item, and receive a transparent quote to avoid hidden charges.

Recommendations for International Patients

Assess your risk first, then decide on screening: Compare yourself against the three high-risk group criteria above. If you meet them, schedule an LDCT promptly; if not, there is no need to follow trends, but remain vigilant.

Choose a reputable institution and specifically request LDCT: When booking, clearly state that you need a "low-dose chest CT without contrast" to avoid inadvertently undergoing a conventional CT with unnecessary radiation.

A pulmonary nodule is not lung cancer: Over 90% are benign, but they must be evaluated by a professional physician. Do not self-diagnose by searching online and frightening yourself.

Dynamic follow-up is more scientific than a "one-size-fits-all" approach: For stable nodules, regular follow-up is the safest strategy. If a nodule changes, timely surgery with minimally invasive techniques can allow discharge within a week.

Leverage telemedicine: For patients residing overseas, Meijiakang supports international remote consultations. You can upload imaging data to the platform, and a top domestic thoracic surgery expert team will provide a second opinion, ensuring your decision is foolproof.

If you need to arrange LDCT screening or have questions about pulmonary nodule management, feel free to contact us for one-on-one consultation. We will match you with the most suitable experts and examination plans. Early-stage lung cancer has an extremely high cure rate; don't let hesitation become regret.